Could a tiny dose of immunotherapy tame tough cancers?

This study tests a low dose of the immunotherapy drug nivolumab, alone or with chemotherapy, in people with advanced colorectal or stomach cancers that have a specific genetic feature (MSI/dMMR). The goal is to see if this approach can shrink tumors before surgery or control the disease when it has spread. About 128 participants will receive different treatment schedules, and researchers will monitor how well the tumors respond and how safe the treatment is.